PUMA BIOTECHNOLOGY, INC. Extinguishment of Debt, Amount
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Extinguishment of Debt, Amount of $102.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt
us-gaap:ExtinguishmentOfDebtAmount · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. extinguishment of debt, amount for the quarter ending 2026-06-30 was $11.34M, a 0.08% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. extinguishment of debt, amount for the quarter ending 2026-03-31 was $90.66M, a 100.00% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. extinguishment of debt, amount for the quarter ending 2025-12-31 was $11.33M, a 0.00% change year-over-year.
- PUMA BIOTECHNOLOGY, INC. extinguishment of debt, amount for the quarter ending 2025-09-30 was $11.33M, a 0.00% change year-over-year.
- PUMA BIOTECHNOLOGY, INC. extinguishment of debt, amount for fiscal 2025 was $79.33M, a 133.34% increase from fiscal 2024.
- PUMA BIOTECHNOLOGY, INC. extinguishment of debt, amount for fiscal 2024 was $34.00M.
| Period end | Extinguishment of Debt, Amount 3 month | Extinguishment of Debt, Amount 6 month | Extinguishment of Debt, Amount 9 month | Extinguishment of Debt, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $102.00M 10-Q · filed 2026-08-06 | $113.33M derived: sum of 3 quarters · filed 2026-08-06 | $124.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $90.66M 10-Q · filed 2026-05-07 | $101.99M derived: sum of 2 quarters · filed 2026-05-07 | $113.32M derived: sum of 3 quarters · filed 2026-05-07 | $124.66M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $11.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.66M derived: sum of 2 quarters · filed 2026-02-26 | $34.00M derived: sum of 3 quarters · filed 2026-02-26 | $79.33M 10-K · filed 2026-02-26 |
| 2025-09-30 | $11.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $22.66M derived: sum of 2 quarters · filed 2025-11-06 | $67.99M 10-Q · filed 2025-11-06 | $79.33M derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | $11.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $56.66M 10-Q · filed 2025-08-07 | $67.99M derived: sum of 3 quarters · filed 2025-08-07 | $79.33M derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | $45.33M 10-Q · filed 2025-05-08 | $56.66M derived: sum of 2 quarters · filed 2025-05-08 | $67.99M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2024-12-31 | $11.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $22.66M derived: sum of 2 quarters · filed 2025-02-27 | $34.00M 10-K · filed 2025-02-27 | |
| 2024-09-30 | $11.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $22.66M 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | $11.33M 10-Q · filed 2024-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |